

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF WYOMING**

HEALTH ADVANCE, INC.,)	
)	
Plaintiff,)	
)	
v.)	Civil Number: 17-CV-132-SWS
)	
JORDAN STARKMAN,)	
)	
Defendant.)	

Affidavit of Jordan Starkman

_____)
_____) ss.
_____)

Jordan Starkman, of legal age, having first been duly sworn upon his oath deposes and says as follows:

- Health Advance, Inc. is a Wyoming corporation, which was incorporated on or about April 14, 2010 by me.
- I incorporated Health Advance as a for-profit, publically traded company.
- The Company operates as an online retailer of home medical products with operations in Canada and the United States.
- Health Advance has 500,000,000 authorized common shares.
- Health Advance is a voluntary filer with the SEC; therefore, it is not required to make filings with the SEC.

- As a voluntary filer and as a small company, Health Advance may be late in some of its filings, which results in a “stop” sign being placed on the OTC Market’s trading platform. The “stop” sign indicates that the filings are not current. A “stop” sign has been in place on Health Advance stock since approximately February 2017, because of the need to wait for completion of an audit of Hantian Labs Limited’s books.

- I, as incorporator, was the sole director on the Board of Directors at the time of Health Advance, Inc.’s incorporation, and later served and continues to serve as President and Director of the Company.

- In March 2011, Domenico Pascazi was appointed as a director; however, he later resigned his position in February 2013.

- On or about October 13, 2016, Health Advance entered into an agreement with Hantian Labs Limited, a private UK corporation (hereinafter referred to as “Hantian” or “Hantian Labs”) whereby Health Advance agreed to acquire 100% interest in Hantian.

- On or about January 6, 2017, Health Advance, by and through me, waived a requirement of the Hantian Labs deal which would have required Hantian to undertake to raise a minimum financing of \$250,000 for marketing of Hantian’s product line.

- The Hantian Labs deal closed on or about January 16, 2017.

- As part of the Hantian Labs deal, shares were issued to various individuals, which increased the number of outstanding shares for the Company.

- Based on information and belief, Health Advance had a total of 50,320,000

shares issued as of March 16, 2017.

- On or about March 1, 2017, Health Advance entered into an employment agreement with me. On the same date, it entered into an employment agreement with Christian Diesveld. Pursuant to these employment agreements, both Mr. Diesveld and I were given the option to elect to receive a one-time payment of shares of the Company in lieu of salary over the next three years. Mr. Diesveld and I both elected to receive the shares in lieu of compensation.

- Christian Diesveld was issued his shares from this employment agreement on May 23, 2017, and I was issued my shares from this employment agreement on June 12, 2017.

- Following the close of the Hantian Labs deal and pursuant to the terms of that deal, Christian Diesveld was appointed to the Board of Directors of Health Advance. With the addition of Mr. Diesveld to the Board of Directors, the Board of Directors has two (2) members: Christian Diesveld and myself.

- On or about March 6, 2017, Health Advance closed a deal with Micro Medtech, Ltd. in which Micro Medtech was to be issued 40,000,000 shares of Health Advance stock.

- Micro Medtech shares were issued on March 23, 2017.

- Following the issuance of the shares to Micro Medtech, Micro Medtech would not have been and was not the majority stock owner of Health Advance as there was approximately 95,000,000 shares issued at that time.

- On or about April 18, 2017, a conference call was held between members of Micro Medtech and me.

- The April 18th conference call was not a formal meeting of the shareholders or of Health Advance, and no committee was ever formed especially an alleged control stock committee.

- During the April 18th the conference call, we discussed Health Advance business in general. Further, members of Micro Medtech on the call voiced their position that they desired me to file a 10-Q with the SEC; however, I indicated that I could not file the requested 10-Q until the audit of Hantian Labs' books was completed. In the end, I informed members of Micro Medtech that filing a 10-Q with the unaudited books of Hantian Labs would be improper, and that I would not be filing the 10-Q until the audit of Hantian Labs' books was completed.

- Without audited books from Hantian Labs, I believed it was improper to file a 10-Q because Health Advance's financials needed to include information from and regarding (including the financials of) the newly acquired company, Hantian Labs. It was my intent to have a 10-Q filed as soon as the audit was completed. However, it was uncertain when that audit would be completed.

- While the April 19, 2017 *Leave of Absence Notice* was allegedly sent to both Christian Diesveld and me, I never received this notice until I received an email in June 2017 with it as an attachment.

- On or about June 12, 2017, Gregory Shusterman – acting as the alleged

Chairman of the Board of Directors – sent a cease and desist letter to me. Mr. Shusterman emailed this cease and desist letter along with the alleged April 2017 leave of absence to me on June 14, 2017. This email was the first time I had received notice of any alleged leave of absence.

- To correct the improper and fraudulent representations of Micro Medtech, I filed an 8-K with the SEC on June 15, 2017, in which I informed the public that Gregory Shusterman was not an officer, director, or employee of Health Advance, Inc. and did not have access to the Company’s internal financial statements or authority to file any reports on behalf of the Company. I also advised the public that the Micro Medtech deal was terminated. I also filed necessary paperwork with the Wyoming Secretary of State to correct the improper removal of him as the proper President of the Company.

- I also issued a press release on behalf of Health Advance on June 15, 2017 in which I advised the public of the improper filing of a 10-Q by Gregory Shusterman.

- Following my June 15th press release, a notice to disregard was issued for my June 15th press release. I contacted Marketwire regarding the notice to disregard and was told that it was issued after Gregory Shusterman called Marketwire and threatened to sue them if a notice to disregard was not issued

- I have reviewed the filings with the SEC that Gregory Shusterman has filed, and they contain numerous inaccuracies and falsities including, but not limited to, the amount of shares, the status of the closer of the Hantian Labs deal, and the financials. The reported financials of the company in Mr. Shusterman’s August 2017 10-Q cannot

be and are not accurate as Micro Medtech and him do not have access to the internal financial records of the Company as they are in my possession and control.

- Health Advance is my Company. My filings, statements, and representations with the SEC and others have all been in good faith in and attempt to protect it from the actions of Micro Medtech and its agents.

FURTHER AFFIANT SAYETH NOT

DATED this _____ day of September, 2017.

By:

Jordan Starkman

_____)
 _____) ss.
 _____)

The foregoing was acknowledged before me by Jordan Starkman this _____ day of September, 2017. Jordan Starkman acknowledges that he has read the foregoing and understands the contents thereof and that he executed the same freely and voluntarily.

Witness my hand and official seal.

Notary Public

My Commission Expires: